Sina Bavari
Corporate Officer/Principal at TONIX PHARMACEUTICALS HOLDING CORP.
Sina Bavari active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TONIX PHARMACEUTICALS HOLDING CORP. | Corporate Officer/Principal | 2022-07-24 | - |
Healion Bio, Inc.
 Healion Bio, Inc. BiotechnologyHealth Technology Part of Tonix Pharmaceuticals Holding Corp., Healion Bio, Inc. is a biotechnology development company based in Frederick, MD. The company is focused on developing the next generation of antiviral compounds, with two antiviral platforms: the HB-100 series of protease inhibitors and the HB-200/300 series of next-generation antiviral biologics. The HB-100 series is a first-in-class antiviral with an orthogonal mechanism of action to existing drugs. The company was founded by Sina Bavari and Simon Newman, with Simon Newman serving as CEO since incorporation. Healion Bio was acquired by Tonix Pharmaceuticals Holding Corp. on February 01, 2023 for $1.20 million. | Director/Board Member | - | - |
| Chief Tech/Sci/R&D Officer | - | - | |
| Founder | - | - |
Career history of Sina Bavari
Former positions of Sina Bavari
| Companies | Position | Start | End |
|---|---|---|---|
| U.S. Army Medical Research Institute for Infectious Diseases | Chief Tech/Sci/R&D Officer | - | - |
Training of Sina Bavari
| University of Nebraska Medical Center | Doctorate Degree |
| University of Southern California | Graduate Degree |
Statistics
International
| United States | 6 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Director/Board Member | 1 |
| Founder | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| TONIX PHARMACEUTICALS HOLDING CORP. | Health Technology |
| Private companies | 1 |
|---|---|
Healion Bio, Inc.
Healion Bio, Inc. BiotechnologyHealth Technology Part of Tonix Pharmaceuticals Holding Corp., Healion Bio, Inc. is a biotechnology development company based in Frederick, MD. The company is focused on developing the next generation of antiviral compounds, with two antiviral platforms: the HB-100 series of protease inhibitors and the HB-200/300 series of next-generation antiviral biologics. The HB-100 series is a first-in-class antiviral with an orthogonal mechanism of action to existing drugs. The company was founded by Sina Bavari and Simon Newman, with Simon Newman serving as CEO since incorporation. Healion Bio was acquired by Tonix Pharmaceuticals Holding Corp. on February 01, 2023 for $1.20 million. | Health Technology |
- Stock Market
- Insiders
- Sina Bavari
- Experience
